{deleted text} shows text that was in HB0207 but was deleted in HB0207S01. inserted text shows text that was not in HB0207 but was inserted into HB0207S01.

DISCLAIMER: This document is provided to assist you in your comparison of the two bills. Sometimes this automated comparison will NOT be completely accurate. Therefore, you need to read the actual bills. This automatically generated document could contain inaccuracies caused by: limitations of the compare program; bad input data; or other causes.

Representative Norman K. Thurston proposes the following substitute bill:

INSULIN ACCESS AMENDMENTS

2020 GENERAL SESSION STATE OF UTAH

Chief Sponsor: Norman K. Thurston

Senate Sponsor:

Cosponsors:	Marie H. Poulson	Mike Winder
Marsha Judkins	Raymond P. Ward	

Lee B. Perry

LONG TITLE

General Description:

This bill creates mechanisms to increase Utahns' access to affordable insulin.

Highlighted Provisions:

This bill:

- creates an incentive for health benefit plans to reduce the required copayments for insulin:
- creates an incentive for the Public Employees' Benefit and Insurance Program to reduce required copayments for insulin;

- directs the Public Employees' Benefit and Insurance Program to purchase insulin at discounted prices and to create a program that allows {public employees} Utahns to {access} purchase the discounted insulin;
 - increases the number of days for which an insulin prescription can be refilled; and
 - {increases the length of time} authorizes a pharmacist to refill an expired insulin prescription { can last;
 - ▶ increases the number of professions that can be licensed to prescribe insulin; and
 - makes technical changes}.

Money Appropriated in this Bill:

None

Other Special Clauses:

This bill provides a special effective date.

Utah Code Sections Affected:


AMENDS:

ENACTS:

```
31A-22-626, as last amended by Laws of Utah 2015, Chapter 258
      58-17b-102, as last amended by Laws of Utah 2019, Chapter 343
      58-17b-501, as last amended by Laws of Utah 2018, Chapter 295
}
      58-17b-609, as last amended by Laws of Utah 2005, Chapter 160
      58-17b-612, as last amended by Laws of Utah 2019, Chapter 343
      58-17b-625, as last amended by Laws of Utah 2019, Chapter 343
      58-31b-102, as last amended by Laws of Utah 2019, Chapter 233
      58-31b-803, as last amended by Laws of Utah 2019, Chapter 233
      62A-4a-213, as last amended by Laws of Utah 2019, Chapter 257
ENACTS:
      26-67-101, Utah Code Annotated 1953
      26-67-102, Utah Code Annotated 1953
      26-67-103, Utah Code Annotated 1953
      26-67-104, Utah Code Annotated 1953
      26-67-105, Utah Code Annotated 1953
```

49-20-420, Utah Code Annotated 1953

```
49-20-421, Utah Code Annotated 1953
}
       58-17b-608.2, Utah Code Annotated 1953
Be it enacted by the Legislature of the state of Utah:
       Section 1. Section \frac{26-67-101}{31A-22-626} is \frac{1}{26-67-101}
CHAPTER 67. INSULIN ACCESS ACT
       26-67-101. Title.
       This chapter is known as the "Insulin Access Act."
       Section 2. Section 26-67-102 is enacted to read:
       26-67-102. Definitions.
      As used in this chapter:
       (1) "Division" means the Division of Occupational and Professional Licensing created
in Section 58-1-103.
      (2) "Insulin" means the same as that term is defined in Section 49-20-421.
      (3) "Local health department" means:
      (a) a local health department, as defined in Section 26A-1-102; or
      (b) a multicounty local health department, as defined in Section 26A-1-102.
      (4) "Patient counseling" means the same as that term is defined in Section 58-17b-102.
       (5) "Pharmacist" means the same as that term is defined in Section 58-17b-102.
      (6) "Pharmacy intern" means the same as that term is defined in Section 58-17b-102.
       (7) "Physician" means the same as that term is defined in Section 26-2-2.
       (8) "Practice of registered nursing" means the same as that term is defined in Section
<del>58-31b-102.</del>
       (9) "Prescribe" means the same as that term is defined in Section 58-17b-102.
       (10) "Registered nurse" means a person licensed under Title 58, Chapter 31b, Nurse
Practice Act, to engage in the practice of registered nursing.
       Section 3. Section 26-67-103 is enacted to read:
       26-67-103. Duty or standard of care.
       This chapter does not create a duty or standard of care for a person to prescribe insulin.
      Section 4. Section 26-67-104 is enacted to read:
       26-67-104. Authorization to prescribe insulin.
```



months; and (d) shall provide the patient with: (i) written information regarding the importance of seeing the patient's primary care physician to obtain recommended tests and screening; and (ii) a copy of the record of the encounter with the patient that includes: (A) the patient's completed self-assessment; and (B) a description of the insulin prescribed or the basis for not prescribing insulin. (2) If a pharmacist, pharmacy intern, or registered nurse prescribes insulin to a patient, the pharmacist, pharmacy intern, or registered nurse shall, at a minimum, provide patient counseling to the patient regarding: (a) the appropriate administration and storage of the insulin; (b) the need for regular checkups with a primary care physician; and (c) the risks associated with not administering the insulin correctly. (3) The division, in collaboration with the Board of Pharmacy, the Board of Nursing, and the Physicians Licensing Board, shall make rules in accordance with Title 63G, Chapter 3. Utah Administrative Rulemaking Act, establishing the self-screening risk assessment described in Subsection (1)(a).

Section 6. Section 31A-22-626 is amended to read:

31A-22-626. Coverage of diabetes.

- (1) As used in this section[, {{}}"diabetes"]:
- (a) "Diabetes" includes individuals with:
- [(a)] <u>(i)</u> complete insulin deficiency or type 1 diabetes;
- [(b)] (ii) insulin resistant with partial insulin deficiency or type 2 diabetes; [and] or
- [(c)] (iii) elevated blood glucose levels induced by pregnancy or gestational diabetes.
- (b) "Lowest tier" means:
- (i) the lowest {copayment} cost tier of a health benefit plan; or
- (ii) the {preventive drug tier} lowest cost-sharing level of a high deductible health plan that preserves the enrollee's ability to claim tax exempt contributions from the enrollee's health savings account under federal laws and regulations.
- (c) "Therapy category" means a type of insulin that is distinct from other types of insulin due to a difference in onset, peak time, or duration.

- (2) The commissioner shall establish, by rule, minimum standards of coverage for diabetes for accident and health insurance policies that provide a health insurance benefit before July 1, 2000.
 - (3) In making rules under Subsection (2), the commissioner shall require rules:
- (a) with durational limits, amount limits, deductibles, and coinsurance for the treatment of diabetes equitable or identical to coverage provided for the treatment of other illnesses or diseases; and
 - (b) that provide coverage for:
- (i) diabetes self-management training and patient management, including medical nutrition therapy as defined by rule, provided by an accredited or certified program and referred by an attending physician within the plan and consistent with the health plan provisions for self-management education:
 - (A) recognized by the federal Centers for Medicare and Medicaid Services; or
 - (B) certified by the Department of Health; and
- (ii) the following equipment, supplies, and appliances to treat diabetes when medically necessary:
 - (A) blood glucose monitors, including those for the legally blind;
 - (B) test strips for blood glucose monitors;
 - (C) visual reading urine and ketone strips;
 - (D) lancets and lancet devices;
 - (E) insulin;
- (F) injection aides, including those adaptable to meet the needs of the legally blind, and infusion delivery systems;
 - (G) syringes:
 - (H) prescriptive oral agents for controlling blood glucose levels; and
 - (I) glucagon kits.
- (4) Beginning January 1, 2021, a health benefit plan that provides coverage for insulin shall:
- (a) cap the total amount that an insured is required to pay for insulin at an amount not to exceed \$30 per prescription of a 30-day supply of insulin {, regardless of the amount or type of insulin needed to fill the insured's prescription}; { and}

- (b) apply the cap to an insured regardless of whether the insured has met the plan's deductible; and
 - (c) apply the cap to at least one insulin in each therapy category.
 - (5) Subsection (4) does not apply to a health plan that:
- (a) covers at least one insulin in each therapy category under the lowest tier of drugs; and
- (b) does not require an insured to meet a deductible before the plan will cover insulin at the lowest tier.
- (6) A health {benefit plan shall reimburse an insured for insulin purchased under Section 49-20-421.
 - Section 7. Section 49-20-420 is enacted to read:
- 49-20-420. Coverage plan described in Subsection (5) may condition coverage of insulin (...
- (1) As used in this section, "lowest tier" means the lowest copayment tier of under the lowest tier on the insured's participation in wellness-related activities for diabetes.
- (4) to a health benefit plan for the preventive drug tier of a high deductible health plan.
 - (2) Beginning January 1, 2021, the program shall:
- (a) cap the total amount that an insured is required to pay for insulin at an amount not to exceed \$30 per 30-day supply of insulin, regardless of the amount or type of insulin needed to fill the insured's prescription; and
- (b) apply the cap to an insured regardless of whether the insured has met the plan's deductible.
- Section 8} if the health benefit plan can demonstrate to the department that the plan provides an insured with substantially similar consumer cost reductions to those that result from Subsections (4) and (5).
- (8) The department shall adjust the cap described in Subsection (4)(a) for inflation based on the seasonally adjusted consumer price index for all urban consumers as published by the Bureau of Labor Statistics of the United States Department of Labor.
- (9) A health benefit plan is not required to reimburse participants in the insulin purchasing program described in Section 49-20-420.

- <u>Section 2</u>. Section $\frac{49-20-421}{49-20-420}$ is enacted to read:
- {49-20-421}49-20-420. Purchasing of insulin.
- (1) As used in this section:
- (a) "Diabetes" means:
- (i) complete insulin deficiency or type 1 diabetes;
- (ii) insulin resistant with partial insulin deficiency or type 2 diabetes; or
- (iii) elevated blood glucose levels induced by pregnancy or gestational diabetes.
- (b) "Discount program" means a process developed by the program that allows participants to purchase insulin at a discounted, post-rebate rate.
- (c) "Individual with diabetes" means an individual who has been diagnosed with diabetes and who uses insulin to treat diabetes.
 - (d) "Insulin" means a prescription drug that contains insulin.
 - (e) "Participant" means a {public employee} resident of Utah who:
 - (i) uses insulin to treat diabetes;
 - (ii) does not receive health coverage under the program; and
 - (iii) {has decided to participate} enrolls in the discount program.
 - (f) "Public employee" means the same as that term is defined in Section 34-32-1.1.
 - (g) "Prescription drug" means the same as that term is defined in Section 58-17b-102.
- (2) {In accordance with Title 63G, Chapter 6A, Utah Procurement}

 Code} Notwithstanding Subsection 49-20-201(1), and for the purpose of the insulin discount

 program only, the program shall {contract with insulin manufacturers to purchase insulin at a discounted price.}
- (3) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the program shall make rules to develop a}offer an insulin discount program to {make the purchased insulin available to }participants{ at a discounted price}.
 - $(\frac{4+3}{3})$ The discount program described in Subsection $(\frac{4+3}{3})$ shall:
- (a) provide a participant with a card or electronic document that identifies the participant as eligible for the discount;
- (b) provide a participant with information about pharmacies that will honor the discount;
 - (c) allow a participant to purchase insulin at {the fully}a discounted, post-rebate price{

described in Subsection (2)}; and

all transaction information.

(d) provide a participant with instructions to pursue a \frac{\text{refund}\text{reimbursement}}{\text{of the}} purchase price from the participant's health insurer. {Section 9. Section 58-17b-102 is amended to read: 58-17b-102. Definitions. In addition to the definitions in Section 58-1-102, as used in this chapter: (1) "Administering" means: (a) the direct application of a prescription drug or device, whether by injection, inhalation, ingestion, or by any other means, to the body of a human patient or research subject by another person; or (b) the placement by a veterinarian with the owner or caretaker of an animal or group of animals of a prescription drug for the purpose of injection, inhalation, ingestion, or any other means directed to the body of the animal by the owner or caretaker in accordance with written or verbal directions of the veterinarian. (2) "Adulterated drug or device" means a drug or device considered adulterated under 21 U.S.C. Sec. 351 (2003). (3) (a) "Analytical laboratory" means a facility in possession of prescription drugs for the purpose of analysis. (b) "Analytical laboratory" does not include a laboratory possessing prescription drugs used as standards and controls in performing drug monitoring or drug screening analysis if the prescription drugs are prediluted in a human or animal body fluid, human or animal body fluid components, organic solvents, or inorganic buffers at a concentration not exceeding one milligram per milliliter when labeled or otherwise designated as being for in vitro diagnostic use. (4) "Animal euthanasia agency" means an agency performing euthanasia on animals by the use of prescription drugs. (5) "Automated pharmacy systems" includes mechanical systems which perform operations or activities, other than compounding or administration, relative to the storage,

(6) "Beyond use date" means the date determined by a pharmacist and placed on a


packaging, dispensing, or distribution of medications, and which collect, control, and maintain

prescription label at the time of dispensing that indicates to the patient or caregiver a time beyond which the contents of the prescription are not recommended to be used. (7) "Board of pharmacy" or "board" means the Utah State Board of Pharmacy created in Section 58-17b-201. (8) "Branch pharmacy" means a pharmacy or other facility in a rural or medically underserved area, used for the storage and dispensing of prescription drugs, which is dependent upon, stocked by, and supervised by a pharmacist in another licensed pharmacy designated and approved by the division as the parent pharmacy. (9) "Centralized prescription processing" means the processing by a pharmacy of a request from another pharmacy to fill or refill a prescription drug order or to perform processing functions such as dispensing, drug utilization review, claims adjudication, refill authorizations, and therapeutic interventions. (10) "Class A pharmacy" means a pharmacy located in Utah that is authorized as a retail pharmacy to compound or dispense a drug or dispense a device to the public under a prescription order. (11) "Class B pharmacy": (a) means a pharmacy located in Utah: (i) that is authorized to provide pharmaceutical care for patients in an institutional setting; and (ii) whose primary purpose is to provide a physical environment for patients to obtain health care services; and (b) (i) includes closed-door, hospital, clinic, nuclear, and branch pharmacies; and (ii) pharmaceutical administration and sterile product preparation facilities. (12) "Class C pharmacy" means a pharmacy that engages in \(\frac{4}{2}\) The discount program shall charge a price for insulin that allows the program to retain only enough of a portion of the {manufacture, production, wholesale, or distribution of drugs or devices in Utah. (13) "Class D pharmacy" means a nonresident pharmacy. (14) "Class E pharmacy" means all other pharmacies. (15) (a) "Closed-door pharmacy" means a pharmacy that: (i) provides pharmaceutical care to a defined and exclusive group of patients who have access to the services of the pharmacy because they are treated by or have an affiliation with a

specific entity, including a health maintenance organization or an infusion company; or (ii) engages exclusively in the practice of telepharmacy and does not serve walk-in retail customers. (b) "Closed-door pharmacy" does not include a hospital pharmacy, a retailer of goods to the general public, or the office of a practitioner. (16) "Collaborative pharmacy practice" means a practice of pharmacy whereby one or more pharmacists have jointly agreed, on a voluntary basis, to work in conjunction with one or more practitioners under protocol whereby the pharmacist may perform certain pharmaceutical care functions authorized by the practitioner or practitioners under certain specified conditions or limitations. (17) "Collaborative pharmacy practice agreement" means a written and signed agreement between one or more pharmacists and one or more practitioners that provides for collaborative pharmacy practice for the purpose of drug therapy management of patients and prevention of disease of human subjects. (18) (a) "Compounding" means the preparation, mixing, assembling, packaging, or labeling of a limited quantity drug, sterile product, or device: (i) as the result of a practitioner's prescription order or initiative based on the practitioner, patient, or pharmacist relationship in the course of professional practice; (ii) for the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale or dispensing; or (iii) in anticipation of prescription drug orders based on routine, regularly observed prescribing patterns. (b) "Compounding" does not include: (i) the preparation of prescription drugs by a pharmacist or pharmacy intern for sale to another pharmacist or pharmaceutical facility; (ii) the preparation by a pharmacist or pharmacy intern of any prescription drug in a dosage form which is regularly and commonly available from a manufacturer in quantities and strengths prescribed by a practitioner; or (iii) the preparation of a prescription drug, sterile product, or device which has been withdrawn from the market for safety reasons.

(19) "Confidential information" has the same meaning as "protected health


information" under the Standards for Privacy of Individually Identifiable Health Information, 45 C.F.R. Parts 160 and 164. (20) "Controlled substance" means the same as that term is defined in Section 58-37-2. (21) "Dietary supplement" has the same meaning as Public Law Title 103, Chapter 417, Sec. 3a(ff) which is incorporated by reference. (22) "Dispense" means the interpretation, evaluation, and implementation of a prescription drug order or device or nonprescription drug or device under a lawful order of a practitioner in a suitable container appropriately labeled for subsequent administration to or use by a patient, research subject, or an animal. (23) "Dispensing medical practitioner" means an individual who is: (a) currently licensed as: (i) a physician and surgeon under Chapter 67, Utah Medical Practice Act; (ii) an osteopathic physician and surgeon under Chapter 68, Utah Osteopathic Medical Practice Act; (iii) a physician assistant under Chapter 70a, Utah Physician Assistant Act; (iv) a nurse practitioner under Chapter 31b, Nurse Practice Act; or (v) an optometrist under Chapter 16a, Utah Optometry Practice Act, if the optometrist is acting within the scope of practice for an optometrist; and (b) licensed by the division under the Pharmacy Practice Act to engage in the practice of a dispensing medical practitioner. (24) "Dispensing medical practitioner clinic pharmacy" means a closed-door pharmacy located within a licensed dispensing medical practitioner's place of practice. (25) "Distribute" means to deliver a drug or device other than by administering or dispensing. (26) (a) "Drug" means: (i) a substance recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or animals; (ii) a substance that is required by any applicable federal or state law or rule to be dispensed by prescription only or is restricted to administration by practitioners only;




(31) "Hospital pharmacy" means a pharmacy providing pharmaceutical care to inpatients of a general acute hospital or specialty hospital licensed by the Department of Health under Title 26, Chapter 21, Health Care Facility Licensing and Inspection Act. (32) "Insulin" means the same as that term is defined in Section 26-47-101. [(32)] (33) "Legend drug" has the same meaning as prescription drug. [(33)] (34) "Licensed pharmacy technician" means an individual licensed with the division, that may, under the supervision of a pharmacist, perform the activities involved in the technician practice of pharmacy. [(34)] (35) "Manufacturer" means a person or business physically located in Utah licensed to be engaged in the manufacturing of drugs or devices. [(35)] (36) (a) "Manufacturing" means: (i) the production, preparation, propagation, conversion, or processing of a drug or device, either directly or indirectly, by extraction from substances of natural origin or independently by means of chemical or biological synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container; and (ii) the promotion and marketing of such drugs or devices. (b) "Manufacturing" includes the preparation and promotion of commercially available products from bulk compounds for resale by pharmacies, practitioners, or other persons. (c) "Manufacturing" does not include the preparation or compounding of a drug by a pharmacist, pharmacy intern, or practitioner for that individual's own use or the preparation, compounding, packaging, labeling of a drug, or incident to research, teaching, or chemical analysis. [(36)] (37) "Medical order" means a lawful order of a practitioner which may include a prescription drug order. [(37)] (38) "Medication profile" or "profile" means a record system maintained as to drugs or devices prescribed for a pharmacy patient to enable a pharmacist or pharmacy intern to analyze the profile to provide pharmaceutical care. -[(38)] (39) "Misbranded drug or device" means a drug or device considered misbranded under 21 U.S.C. Sec. 352 (2003). [(39)] (40) (a) "Nonprescription drug" means a drug which:

(i) may be sold without a prescription; and (ii) is labeled for use by the consumer in accordance with federal law. (b) "Nonprescription drug" includes homeopathic remedies. [(40)] (41) "Nonresident pharmacy" means a pharmacy located outside of Utah that sells to a person in Utah. [(41)] (42) "Nuclear pharmacy" means a pharmacy providing radio-pharmaceutical service. [(42)] (43) "Out-of-state mail service pharmacy" means a pharmaceutical facility located outside the state that is licensed and in good standing in another state, that: (a) ships, mails, or delivers by any lawful means a dispensed legend drug to a patient in this state pursuant to a lawfully issued prescription; (b) provides information to a patient in this state on drugs or devices which may include, but is not limited to, advice relating to therapeutic values, potential hazards, and uses; <u>01</u> (c) counsels pharmacy patients residing in this state concerning adverse and therapeutic effects of drugs. [(43)] (44) "Patient counseling" means the written and oral communication by the pharmacist or pharmacy intern of information, to the patient or caregiver, in order to ensure proper use of drugs, devices, and dietary supplements. [(44)] (45) "Pharmaceutical administration facility" means a facility, agency, or institution in which: (a) prescription drugs or devices are held, stored, or are otherwise under the control of the facility or agency for administration to patients of that facility or agency; (b) prescription drugs are dispensed to the facility or agency by a licensed pharmacist or pharmacy intern with whom the facility has established a prescription drug supervising relationship under which the pharmacist or pharmacy intern provides counseling to the facility or agency staff as required, and oversees drug control, accounting, and destruction; and (c) prescription drugs are professionally administered in accordance with the order of a practitioner by an employee or agent of the facility or agency. [(45)] (46) (a) "Pharmaceutical care" means carrying out the following in collaboration with a prescribing practitioner, and in accordance with division rule:

(i) designing, implementing, and monitoring a therapeutic drug plan intended to
achieve favorable outcomes related to a specific patient for the purpose of curing or preventing
the patient's disease;
(ii) eliminating or reducing a patient's symptoms; or
(iii) arresting or slowing a disease process.
(b) "Pharmaceutical care" does not include prescribing of drugs without consent of a
prescribing practitioner.
[(46)] (47) "Pharmaceutical facility" means a business engaged in the dispensing,
delivering, distributing, manufacturing, or wholesaling of prescription drugs or devices within
or into this state.
[(47)] (48) (a) "Pharmaceutical wholesaler or distributor" means a pharmaceutical
facility engaged in the business of wholesale vending or selling of a prescription drug or device
to other than a consumer or user of the prescription drug or device that the pharmaceutical
facility has not produced, manufactured, compounded, or dispensed.
(b) "Pharmaceutical wholesaler or distributor" does not include a pharmaceutical
facility carrying out the following business activities:
(i) intracompany sales;
(ii) the sale, purchase, or trade of a prescription drug or device, or an offer to sell,
purchase, or trade a prescription drug or device, if the activity is carried out between one or
more of the following entities under common ownership or common administrative control, as
defined by division rule:
(A) hospitals;
(B) pharmacies;
(C) chain pharmacy warehouses, as defined by division rule; or
(D) other health care entities, as defined by division rule;
(iii) the sale, purchase, or trade of a prescription drug or device, or an offer to sell,
purchase, or trade a prescription drug or device, for emergency medical reasons, including
supplying another pharmaceutical facility with a limited quantity of a drug, if:
(A) the facility is unable to obtain the drug through a normal distribution channel in
sufficient time to eliminate the risk of harm to a patient that would result from a delay in
obtaining the drage and



pharmacy, specifically relating to the dispensing of a prescription drug in accordance with Part 8, Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, and division rule adopted after consultation with the Board of pharmacy and the governing boards of the practitioners described in Subsection (23)(a). (b) "Practice as a dispensing medical practitioner" does not include: (i) using a vending type of dispenser as defined by the division by administrative rule; 01 (ii) except as permitted by Section 58-17b-805, dispensing of a controlled substance as defined in Section 58-37-2. [(56)] (57) "Practice as a licensed pharmacy technician" means engaging in practice as a pharmacy technician under the general supervision of a licensed pharmacist and in accordance with a scope of practice defined by division rule made in collaboration with the board. [(57)] (58) "Practice of pharmacy" includes the following: (a) providing pharmaceutical care; (b) collaborative pharmacy practice in accordance with a collaborative pharmacy practice agreement; (c) compounding, packaging, labeling, dispensing, administering, and the coincident distribution of prescription drugs or devices, provided that the administration of a prescription drug or device is: (i) pursuant to a lawful order of a practitioner when one is required by law; and (ii) in accordance with written guidelines or protocols: (A) established by the licensed facility in which the prescription drug or device is to be administered on an inpatient basis; or (B) approved by the division, in collaboration with the board and the Physicians Licensing Board, created in Section 58-67-201, if the prescription drug or device is to be administered on an outpatient basis solely by a licensed pharmacist; (d) participating in drug utilization review; (e) ensuring proper and safe storage of drugs and devices; (f) maintaining records of drugs and devices in accordance with state and federal law and the standards and ethics of the profession;



[(63)] (64) "Prescription device" means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, and any component part or accessory, which is required under federal or state law to be prescribed by a practitioner and dispensed by or through a person or entity licensed under this chapter or exempt from licensure under this chapter. [(64)] (65) "Prescription drug" means a drug that is required by federal or state law or rule to be dispensed only by prescription or is restricted to administration only by practitioners. [(65)] (66) "Repackage": (a) means changing the container, wrapper, or labeling to further the distribution of a prescription drug; and (b) does not include: (i) Subsection [(65)] (66)(a) when completed by the pharmacist responsible for dispensing the product to a patient; or (ii) changing or altering a label as necessary for a dispensing practitioner under Part 8, Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, for dispensing a product to a patient. [(66)] (67) "Research using pharmaceuticals" means research: (a) conducted in a research facility, as defined by division rule, that is associated with a university or college in the state accredited by the Northwest Commission on Colleges and Universities; (b) requiring the use of a controlled substance, prescription drug, or prescription device; (c) that uses the controlled substance, prescription drug, or prescription device in accordance with standard research protocols and techniques, including, if required, those approved by an institutional review committee; and (d) that includes any documentation required for the conduct of the research and the handling of the controlled substance, prescription drug, or prescription device. [(67)] (68) "Retail pharmacy" means a pharmaceutical facility dispensing prescription drugs and devices to the general public. [(68)] (69) (a) "Self-administered hormonal contraceptive" means a self-administered hormonal contraceptive that is approved by the United States Food and Drug Administration to

prevent pregnancy. (b) "Self-administered hormonal contraceptive" includes an oral hormonal contraceptive, a hormonal vaginal ring, and a hormonal contraceptive patch. (c) "Self-administered hormonal contraceptive" does not include any drug intended to induce an abortion, as that term is defined in Section 76-7-301. [(69)] (70) "Self-audit" means an internal evaluation of a pharmacy to determine compliance with this chapter. [(70)] (71) "Supervising pharmacist" means a pharmacist who is overseeing the operation of the pharmacy during a given day or shift. [(71)] (72) "Supportive personnel" means unlicensed individuals who: (a) may assist a pharmacist, pharmacist preceptor, pharmacy intern, or licensed pharmacy technician in nonjudgmental duties not included in the definition of the practice of pharmacy, practice of a pharmacy intern, or practice of a licensed pharmacy technician, and as those duties may be further defined by division rule adopted in collaboration with the board; and (b) are supervised by a pharmacist in accordance with rules adopted by the division in collaboration with the board. [(72)] (73) "Unlawful conduct" means the same as that term is defined in Sections 58-1-501 and 58-17b-501. [(73)] (74) "Unprofessional conduct" means the same as that term is defined in Sections 58-1-501 and 58-17b-502 and may be further defined by rule. [(74)] (75) "Veterinary pharmaceutical facility" means a pharmaceutical facility that dispenses drugs intended for use by animals or for sale to veterinarians for the administration for animals. Section 10. Section 58-17b-501 is amended to read: 58-17b-501. Unlawful conduct. "Unlawful conduct" includes: (1) knowingly preventing or refusing to permit an authorized agent of the division to conduct an inspection pursuant to Section 58-17b-103; (2) failing to deliver the license, permit, or certificate to the division upon demand, if it

has been revoked, suspended, or refused;

(3) (a) using the title "pharmacist," "druggist," "pharmacy intern," "pharmacy technician," or a term having similar meaning, except by a person licensed as a pharmacist, pharmacy intern, or pharmacy technician; or (b) conducting or transacting business under a name that contains, as part of that name, the words "drugstore," "pharmacy," "drugs," "medicine store," "medicines," "drug shop," "apothecary," "prescriptions," or a term having a similar meaning, or in any manner advertising, otherwise describing, or referring to the place of the conducted business or profession, unless the place is a pharmacy issued a license by the division, except an establishment selling nonprescription drugs and supplies may display signs bearing the words "packaged drugs," "drug sundries," or "nonprescription drugs," and is not considered to be a pharmacy or drugstore by reason of the display; (4) buying, selling, causing to be sold, or offering for sale, a drug or device that bears, or the package bears or originally did bear, the inscription "sample," "not for resale," "for investigational or experimental use only," or other similar words, except when a cost is incurred in the bona fide acquisition of an investigational or experimental drug; (5) using to a person's own advantages or revealing to anyone other than the division, board, and its authorized representatives, or to the courts, when relevant to a judicial or administrative proceeding under this chapter, information acquired under authority of this chapter or concerning a method of process that is a trade secret; (6) procuring or attempting to procure a drug or to have someone else procure or attempt to procure a drug: (a) by fraud, deceit, misrepresentation, or subterfuge; (b) by forgery or alteration of a prescription or a written order; (c) by concealment of a material fact; (d) by use of a false statement in a prescription, chart, order, or report; or (e) by theft; (7) filling, refilling, or advertising the filling or refilling of prescriptions for a consumer or patient residing in this state if the person is not licensed: (a) under this chapter; or (b) in the state from which he is dispensing; (8) requiring an employed pharmacist, pharmacy intern, pharmacy technician, or

- authorized supportive personnel to engage in conduct in violation of this chapter; (9) being in possession of a prescription drug for an unlawful purpose; (10) dispensing a prescription drug to a person who does not have a prescription from a practitioner, except as permitted under: (a) Title 26, Chapter 55, Opiate Overdose Response Act; [or] (b) Title 26, Chapter 64, Family Planning Access Act; or (c) Title 26, Chapter 67, Insulin Access Act; (11) dispensing a prescription drug to a person who the person dispensing the drug knows or should know is attempting to obtain drugs by fraud or misrepresentation; (12) selling, dispensing, distributing, or otherwise trafficking in prescription drugs when not licensed to do so or when not exempted from licensure; and (13) a person using a prescription drug or controlled substance that was not lawfully prescribed for the person by a practitioner. Section 11} manufacturer rebate to make the state risk pool whole for providing insulin to Utahns at a lower cost and a lower point of sale. Section 3. Section 58-17b-608.2 is enacted to read: 58-17b-608.2. Insulin prescriptions. (1) As used in this section, "insulin" means a prescription drug that contains insulin. (2) Even if a prescription for insulin is written for a supply for 30 days, a pharmacist may dispense an amount up to a supply for 90 days. (3) If a prescription for insulin {includes authorization for one or more refills} expires, a pharmacist {or a pharmacy intern may dispense one or more of the refills} may dispense a refill for the expired prescription, based on the prescriber's instructions: (a) in an amount up to a supply for 90 days { based on the prescriber's instructions if: (a) the patient has previously had the prescription}; and (b) \filling\if the prescription \fis consistent with\expired no earlier than six months before the \{\text{training and experience of}\}\)date the pharmacist \{\text{or pharmacy intern.}\} (2) If dispenses the refill.
- (4) A pharmacist may dispense insulin for an expired prescription described in Subsection (3) no more than one time per expired prescription.
 - (5) When filling a prescription for insulin { includes authorization for one or more

refills, a pharamcist or a pharmacy intern may dispense one or more of the refills in an amount to exceed 90 days if:

- (a) the patient has previously had the prescription;
- (b) filling the prescription is consistent with the training and experience of the pharmacist or pharmacy intern; and
 - (c) circumstances justify filling the prescription for longer.
- (3) A practitioner is authorized to issue }, a pharmacist may dispense the pharmaceutical equivalent of the insulin prescribed.
- (6) A pharmacist may dispense the therapeutic equivalent when filling a prescription for { insulin that is refillable for up to three years.

Section 12}:

- (a) a glucometer;
- (b) diabetes test strips;
- (c) lancets; or
- (d) syringes.
- (7) Before a pharmacist may dispense insulin under Subsection (2) or (3), the pharmacist shall:
- (a) attempt to contact the prescribing practitioner to inform the prescribing practitioner that the pharmacist intends to dispense insulin under Subsection (2) or (3); and
 - (b) notify the patient of the outcome of the attempt described in Subsection (7)(a).
- (8) Within 30 days after the day on which the pharmacist dispenses insulin under Subsection (2) or (3), the pharmacist shall inform the prescribing practitioner of:
 - (a) the amount of insulin dispensed; and
 - (b) the type of insulin dispensed.

Section 4. Section 58-17b-609 is amended to read:


- 58-17b-609. Limitation on prescriptions and refills -- Controlled Substances Act not affected -- Legend drugs.
- (1) Except as provided in [Sections 58-16a-102 and 58-17b-608.2, a prescription for any prescription drug or device may not be dispensed after one year from the date it was initiated except as otherwise provided in Chapter 37, Utah Controlled Substances Act.


- (2) [A] Except as provided in Section 58-17b-608.2, a prescription authorized to be refilled may not be refilled after one year from the original issue date.
- (3) A practitioner may not be prohibited from issuing a new prescription for the same drug orally, in writing, or by electronic transmission.
 - (4) Nothing in this chapter affects Chapter 37, Utah Controlled Substances Act.
- (5) A prescription for a legend drug written by a licensed prescribing practitioner in another state may be filled or refilled by a pharmacist or pharmacy intern in this state if the pharmacist or pharmacy intern verifies that the prescription is valid.


Section {13. Section 58-17b-612 is amended to read:


58-17b-612. Supervision -- Pharmacist-in-charge.


- (1) (a) Any pharmacy, except a wholesaler, distributor, out-of-state mail service pharmacy, or class E pharmacy, shall be under the general supervision of at least one pharmacist licensed to practice in Utah. One pharmacist licensed in Utah shall be designated as the pharmacist-in-charge, whose responsibility it is to oversee the operation of the pharmacy.
- (b) Notwithstanding Subsection 58-17b-102[(70)](71), a supervising pharmacist does not have to be in the pharmacy or care facility but shall be available via a telepharmacy system for immediate contact with the supervised pharmacy technician or pharmacy intern if:
- (i) the pharmacy is located in an area of need as defined by the division, in consultation with the board, by rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act;
- (ii) the supervising pharmacist described in Subsection (1)(a) is not available;
- (iii) the telepharmacy system maintains records and files quarterly reports as required by division rule to assure that patient safety is not compromised; and
 - (iv) the arrangement is approved by the division in collaboration with the board.
- (c) Subsection (1)(b) applies to a pharmacy that is located in a hospital only if the hospital is controlled by a local board that owns no more than two hospitals; and
- (d) A supervising pharmacist may not supervise more than two pharmacies simultaneously under Subsection (1)(b).
- (2) Each out-of-state mail service pharmacy shall designate and identify to the division a pharmacist holding a current license in good standing issued by the state in which the pharmacy is located and who serves as the pharmacist-in-charge for all purposes under this














nurse within the generally recognized scope of practice of registered nurses as defined by rule[. Registered nursing acts include], including: (a) assessing the health status of individuals and groups; (b) identifying health care needs; (c) establishing goals to meet identified health care needs; (d) planning a strategy of care; (e) prescribing nursing interventions to implement the strategy of care; (f) implementing the strategy of care; (g) maintaining safe and effective nursing care that is rendered to a patient directly or indirectly; (h) evaluating responses to interventions; (i) teaching the theory and practice of nursing; [and] (j) managing and supervising the practice of nursing[.]; and (k) prescribing insulin in accordance with Title 26, Chapter 67, Insulin Access Act. (19) "Prescribe" means the same as that term is defined in Section 58-17b-102. [(18)] (20) "Routine medications": (a) means established medications administered to a medically stable individual as determined by a licensed health care practitioner or in consultation with a licensed medical practitioner; and (b) is limited to medications that are administered by the following routes: (i) oral; (ii) sublingual; (iii) buccal; (iv) eye; (v) ear; (vi) nasal; (vii) rectal; (viii) vaginal; (ix) skin ointments, topical including patches and transdermal; (x) premeasured medication delivered by aerosol/nebulizer; and (xi) medications delivered by metered hand-held inhalers.







31A-22-626 and 49-20-420 take effect on January 1, 2021.